Analyst Jill Wu Raises Target Price and Reiterates Buy on Innovent Biologics After Strong 1H26 Beat and Robust Growth Outlook
Tip Ranks·- CMB International Securities analyst Jill Wu maintained a Buy rating on Innovent Biologics and raised the price target to HK$ 130.25 following a strong 1H26 earnings beat. - The positive rating is driven by robust product sales, expanding global presence, promising pipeline assets, and strategic alliances with Takeda and Pfizer. - These factors, alongside upcoming clinical and regulatory milestones, reinforce confidence in meeting management's long-term revenue targets for 2027 and 2030.Top 5 HK Stock Gainers/Losers (>100B) (8.26)
Top Gainers&Losers·- On August 26, the Hang Seng Index rose 0.56 % and the Hang Seng Tech Index increased by 0.82 %. - Jiangxi Copper Company and Innovent Biologics recorded significant gains of 9.92 % and 9.69 % respectively. - Shandong Gold and Geely Automobile experienced declines of 3.33 % and 3.27 % respectively.HK Midday: HSI Jumps Over 200 pts; Insurers, Brokers Surge; Xiaomi Up 3%+
Market Pulse·- On August 26 afternoon, Hong Kong stocks extended gains with the Hang Seng Index rising 0.83 % to 25722.75 points and the Hang Seng Tech Index up 1.35 %. - Technology stocks, internal insurance and brokerage shares, and new energy power stocks experienced a collective surge, while real estate and individual sectors showed divergence. - Market activity was driven by positive corporate earnings, solid dividend distribution plans, and strategic business expansions such as Alibaba launching its international office AI platform.Innovent Biologics surged 8% on H1 profit beat, broker upgrades
HK Stock Market Update·